Phase 2
N=216
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Meningococcal Disease
Bottom Line
View on ClinicalTrials.gov: NCT00488683 ↗Enrolled (actual)
216
Serious AEs
7.9%
Results posted
Aug 2014
Primary outcome: Primary: Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y — 2.10; 1.80; 1.72; 2.57 B cells per 2x100000 lymphocytes — p=0.69
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- MenACWY-CRM (Biological); DTaP-Hib-IPV (Biological); PCV (Biological); MMR (Biological); Hib (Biological)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Novartis Vaccines
- Primary completion
- May 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y |
2.10; 1.80; 1.72; 2.57; 1.71; 2.43 | 0.69 |
| SECONDARY Memory B Cells by Serogroup A, C, W-135 and Y |
NA; NA; NA | 0.70 |
| SECONDARY Memory B Cells Per 2x100000 by Serogroup A,C, W-135 and Y at One Month After Primary MenACWY-CRM Vaccination and Third MenACWY-CRM Vaccination |
NA; NA; NA | 0.46 |
| SECONDARY Memory B Cells 1 Month After Primary Vaccination and Rise From Pre-third Dose to 1 Month After Third Dose of MenACWY-CRM Vaccination |
NA; NA; NA | 0.59 |
| SECONDARY Memory B Cells 1 Month After Primary Vaccination and 1 Week After Third Vaccination by Serogroup A, C, W-135 and Y |
NA | 0.68 |
| SECONDARY CRM197 Specific Memory B Cells 1 Month After Primary Vaccination and at 12 Months of Age and One Month After MenACWY-CRM Third Vaccination |
NA; NA; NA | 0.0006 sig |
| SECONDARY Increase in Serogroup A, C, W-135 and Y Specific Memory B Cells Before and 1 Month After MenACWY-CRM Booster Vaccination at 12 Months of Age Administered Concomitantly With Pneumococcal Conjugate Vaccine or Alone |
1.811; 1.988; 1.692; 6.429; 6.527; 7.488 | — |
| SECONDARY Increase in Serogroup A, C, W-135 and Y Specific hSBA Titers Before and 1 Month After MenACWY-CRM Booster Vaccination at 12 Months of Age Administered Concomitantly With Pneumococcal Conjugate Vaccine or Alone |
2.2; 2; 2.14; 65; 48; 67 | — |
| SECONDARY Serogroups A, C, W-135 and Y Specific Memory B Cell Response in Children Lacking a hSBA Titer of ≥1:8 One Month After MenACWY-CRM Primary Vaccination |
1.533; 1.391; 1.250; 2.667; 1.250; 1.250 | — |
| SECONDARY Serogroup A, C, W-135 and Y Specific Memory B Cells and Plasma B Cells After MenACWY-CRM Primary Vaccination |
1.25; 3.889; 2.343; 1.97; 1.25; 1.845 | — |
| SECONDARY Serogroup A, C, W-135 and Y Specific hSBA Titers After MenACWY-CRM Primary Vaccination |
2; 13; 26; 9.79; 9.53; 2.63 | — |
| SECONDARY Correlation and Linear Regression Coefficients Between Serogroup A, C, W-135 and Y Specific Memory B Cells 1 Month After MenACWY-CRM Primary Vaccination and IgG Concentration at Day 1 in the Serum of Mothers of Infants |
NA; NA; NA | 0.70 |
| SECONDARY Linear Regression Coefficients (1) Between Serogroup A, C, W-135 and Y Memory B at 5 Months and hSBA Titers at 12 Months, (2) Between Serogroup A, C, W-135 and Y Memory B at 5 Months and IgG at 12 Months, After a 2-Dose Primary Course of MenACWY-CRM |
NA; NA; NA | — |
| SECONDARY Linear Regression Coefficients (1) Between Serogroup A, C, W-135 and Y Memory B Cells at 5 Months and Rise in hSBA Titers, (2) Between Serogroup A, C, W-135 and Y Memory B Cells at 5 Months and Rise in IgG, After Third Dose of MenACWY-CRM at 12 Months |
NA; NA; NA | 0.0436 sig |
| SECONDARY Percentage of Subjects Who Reported Injection Site Local Reactions After Each MenACWY-CRM and Routine Infant Vaccinations. |
32; 35; 22; 19; 28; 17 | — |
| SECONDARY Percentage of Subjects Who Reported Solicited Systemic Reactions After MenACWY-CRM and Routine Infants Primary Vaccinations |
19; 20; 30; 18; 15; 17 | — |
| SECONDARY Percentage of Subjects Who Reported Injection Site Local Reactions After MenACWY-CRM and PCV Vaccinations at 12 Months of Age |
28; 28; 19; 99; 92; 94 | — |
| SECONDARY Percentage of Subjects Who Reported Solicited Systemic Reactions After MenACWY-CRM and PCV Vaccination at 12 Months of Age |
23; 23; 31; 20; 24; 25 | — |
| SECONDARY Increase in Serogroup A, C, W-135 and Y Specific IgG Concentrations Before and 1 Month After MenACWY-CRM Booster Vaccination at 12 Months of Age Administered Concomitantly With Pneumococcal Conjugate Vaccine or Alone |
0.37; 0.33; 0.31; 4.59; 3.5; 5.18 | — |
| SECONDARY Serogroup A, C, W-135 and Y Specific IgG Concentrations After MenACWY-CRM Primary Vaccination |
0.98; 2.23; 2.27; 1.29; 1.39; 0.94 | — |
Summary
This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific serum bactericidal activity using human complement (hSBA) of (respectively) serogroup A, C, W-135 and Y at 12 months of age
Eligibility Criteria
Inclusion Criteria
Subjects who were eligible to be enrolled in the study:
- healthy infants aged 2 months (56 - 83 days old, inclusive);
- available for the visits scheduled in the study;
- mother available for blood draw at Visit 1;
- good health as determined by the clinical judgement of the investigator;
- whose parents gave written informed consent for the infant to be enrolled in the study. The infant's parents must have been willing for the infant to receive the full primary immunization course.
Exclusion Criteria
Subjects who were not eligible for the study were those:
- whose parents had not given or were unwilling or unable to give written informed consent to their child's participation in the study
- with known hypersensitivity to any vaccines contained within the routine immunization schedule
- with unacceptable concurrent illnesses or conditions - e.g.:
- a severe acute or chronic illness; with any present or suspected serious disease such as metabolic, cardiac or autoimmune disease or insulin dependent diabetes or with any other serious disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;
- a genetic anomaly, e.g. Down's syndrome;
- any immunodeficiency, including use of systemic corticosteroids;
- born at less than 36 weeks gestation;
- weighing less than 2.5 kg at birth;
- previous clinical or bacteriological diagnosis of meningitis, or with a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitidis disease;
- known bleeding diathesis, or any condition associated with a prolonged bleeding time;
- who have received any prohibited prior or concomitant medications - e.g.:
- any immunizations within the 30 days prior to enrollment, with the exception of BCG or hepatitis B;
- immunoglobulin;
- any blood products;
- participating in any other clinical trial either currently or in the previous month;
- unable to adhere to the protocol, including plans to move from the area;
- Other:
Had any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Data sourced from ClinicalTrials.gov (NCT00488683). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.